ESTRO 2020 Abstract book

S736 ESTRO 2020

2. CONCORDE (in set up): Ph1 platform study evaluating five DNA damage response inhibitors (DDRi) combined with radiotherapy (RT) (66Gy) in stage IIB/III non-small cell lung cancer. Each study 3:1 randomised novel RT vs RT alone. Primary outcome: DLT within 3 months of RT. 3. ARTEMIS (awaiting funding outcome): Ph2 platform study evaluating multiple intensification CRT strategies to improve organ preservation in locally advanced rectal cancer. Four novel trial arms combining CRT with (1) immune modulator (2) antiangiogenic (3) RT dose escalation or (4) total neoadjuvant treatment vs single control arm of standard CRT. Primary outcome: 30 month organ preservation rate. Benefits: Evaluation of multiple research questions with substantial cost efficiency, single protocol, single funding application, standardisation of methodology, radiotherapy QA, site set up. Efficiencies in CRF, database design and trial monitoring. Greater opportunities for translational research and development of the next generation of clinical trialists. Limitations: Complexity and greater preparation time to design; requires significant clinical trial unit staffing; statistical considerations for adaptive designs with starting and stopping rules both for the trial arms and overall trial. Conclusion We share our experience of three radiotherapy platform trials to encourage investigators to consider this approach. PO-1304 The patient´s perspective on radiotherapy on a 1.5 T MR-Linac J. Ehlers 1 , C. Gani 1,2 , C. Marks 1 , A. Stolte 1 , D. Thorwarth 2,3 , N. Weidner 1 , A. Müller 1,2 , D. Mönnich 3 , M. Nachbar 3 , O. Dohm 1 , D. Zips 1,2 , S. Boeke 1,2 1 University Hospital and Medical Faculty. Eberhard Karls University Tübingen, Department of Radiation Oncology, Tübingen, Germany ; 2 German Cancer Consortium DKTK- partner side Tübingen, and German Cancer Research Center DKFZ, Heidelberg, Germany ; 3 University Hospital and Medical Faculty. Eberhard Karls University Tübingen, Section for Biomedical Physics- Department of Radiation Oncology, Tübingen, Germany Purpose or Objective Hybrid devices using a linear accelerator and a 1.5 T MRI (MRL) are a new development in radiation oncology. The current study investigates whether device-specific factors, such as design of the device, duration of therapy or noise levels, could limit patient´s compliance. In addition, patient reported outcome measures (PROMs) are gaining increasing importance in clinical routine. Material and Methods All patients treated on the MRL in our institution since initiation of treatments in September 2018 were Invited to fill out a weekly patient-reported outcome measures (PROMs) questionnaire (adapted from Ahlander et al., Journal of Advanced Nursing, 2016 and Olausson, tipsRO, 2017) was issued weekly to all patients treated on the MRL in our institution since initiation of treatments in September 2018. The scale recorded values between 0 for none, 1 for light, 2 for moderate and 3 for high level of burden of the item being interrogated. Queried items are shown in table 1.

Results A total of 81 patients could be evaluated. Fir an individual patient, the highest score during treatment was used. For better understanding, the possible answers were sorted by degree of stress from not at all (score 0) to very stressful (score 3). A total of 30% of the patients said they had forced themselves to get through the situation (score 2 or 3), but completed the factions on schedule. The treatment time (mean 35 minutes) was felt to be tolerable in over 80% of the patients (Score 0 or 1). The patient positioning was rated as comfortable by more than 80% (Score 0 or 1). A feeling of warmth was reported by 40% of the patients (Score 2 or 3). In addition, 26% and 5% reported mild or severe dizziness immediately after treatment, respectively. A desire for more communication with the team during radiation therapy was expressed by 33% and 35% wanted more information about treatment, although nearly all patients stated they understood the treatment. Conclusion Overall, based on PROMs the treatment at the MRL was tolerated very well. There was no interruption of the daily radiation or series on the MRL on request of the patient. Treatment time was considered tolerable for more than 80%. Results on potential sources of distress will be used for better counselling future patients and optimization of MRL procedures. To allow for a better understanding of the results obtained at the MRL, we have started an investigation in a control group treated at a conventional Linac. Preliminary results show no significant differences compared to the presented cohort. PROMs are a useful tool for assessing the burden of treatment on a MRL. PO-1305 Effectiveness and safety evaluation of radiotherapy for Painful Heel Spur Syndrome. T. Latusek 1 , L. Miszczyk 1 1 Maria Sklodowska- Curie Memorial Cancer Center and Purpose or Objective Painful Hell Spur (Heel Spur Syndrome - HSS) is a skeletal disorder and one of the most common foot complaint significantly decreasing patients quality of life due to pain and mobility problems. Radiotherapy (RT) represents one of the most valuable options for treating HSS. The aim of the study was to evaluate the efficacy and safety of RT in The study group consisted of 55 consecutive patients with HSS irradiated between 2013–2016 on the linear accelerators. All patients were irradiated to a total dose of 6 Gy given in 6 fractions five times weekly. Patients’ medical records have been analyzed retrospectively and telephone survey has been carried out. We assessed several aspects concerning: pain duration before RT, heel injury, walking possibility and pain in Heel Score according Institute of Oncology Warsaw Gliwice Branch, Radiotherapy Department, Gliwice, Poland the treatment of HSS. Material and Methods